Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
暂无分享,去创建一个
F. Marincola | P. Choyke | M. Merino | S. Rosenberg | P. Hwu | D. Reintgen | B. Pockaj | T. Kuzel | L. Riley | Donald M Miller | H. Kaufman | D. Schwartzentruber | B. Curti | E. Whitman | J. Richards | K. Conlon | K. Kendra | F. Gailani | J. Treisman | R. Conry | Rene Gonzalez | D. Lawson | D. Vena | R. White | J. Balkissoon | P. D. Leming | Rene C. Gonzalez | Donald M Miller
[1] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[2] P. Kantoff,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.
[3] R. Blasberg,et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts , 2010, The Journal of experimental medicine.
[4] N. Zeps,et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. Sharma,et al. CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients , 2008, Proceedings of the National Academy of Sciences.
[6] S. Steinberg,et al. Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines , 2008, Clinical Cancer Research.
[7] B. LaFleur,et al. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] P. Hwu,et al. Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy , 2007, Clinical Cancer Research.
[9] J. Allison,et al. Checkpoint blockade in cancer immunotherapy. , 2007, Advances in immunology.
[10] S. Rosenberg,et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] E. Bissonette,et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] N. Restifo,et al. The future of interleukin-2: enhancing therapeutic anticancer vaccines. , 2000, The cancer journal from Scientific American.
[13] F. Marincola,et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. , 1999, Journal of immunology.
[14] R. Fisher,et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] F. Marincola,et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.